Adaptive Biotechnologies (ADPT) Expected to Announce Earnings on Tuesday

Adaptive Biotechnologies (NASDAQ:ADPT) will likely be posting its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect Adaptive Biotechnologies to post earnings of ($0.16) per share and revenue of $61.0340 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. During the same quarter in the previous year, the firm earned ($0.23) EPS. The company’s quarterly revenue was up 51.0% compared to the same quarter last year. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Adaptive Biotechnologies Stock Up 1.2%

NASDAQ ADPT opened at $14.27 on Friday. Adaptive Biotechnologies has a 52 week low of $8.38 and a 52 week high of $20.76. The business’s fifty day simple moving average is $14.35 and its 200-day simple moving average is $15.94. The firm has a market cap of $2.28 billion, a PE ratio of -35.67 and a beta of 2.16.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Guggenheim lifted their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, January 26th. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. BTIG Research upped their target price on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Finally, JPMorgan Chase & Co. upped their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.43.

Insider Buying and Selling

In other Adaptive Biotechnologies news, COO Julie Rubinstein sold 141,583 shares of the business’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.29, for a total transaction of $1,881,638.07. Following the sale, the chief operating officer directly owned 516,610 shares in the company, valued at $6,865,746.90. This represents a 21.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sharon Benzeno sold 63,103 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total transaction of $831,066.51. Following the sale, the insider owned 272,751 shares in the company, valued at $3,592,130.67. This trade represents a 18.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,587,099 shares of company stock valued at $37,296,664 over the last three months. Company insiders own 6.40% of the company’s stock.

Institutional Trading of Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System increased its stake in Adaptive Biotechnologies by 1.0% during the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after purchasing an additional 933 shares during the period. Captrust Financial Advisors increased its stake in Adaptive Biotechnologies by 7.6% during the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after purchasing an additional 1,119 shares during the period. Panagora Asset Management Inc. increased its stake in Adaptive Biotechnologies by 1.2% during the fourth quarter. Panagora Asset Management Inc. now owns 164,737 shares of the company’s stock worth $2,675,000 after purchasing an additional 1,945 shares during the period. Corient Private Wealth LLC increased its stake in Adaptive Biotechnologies by 3.4% during the fourth quarter. Corient Private Wealth LLC now owns 71,908 shares of the company’s stock worth $1,168,000 after purchasing an additional 2,347 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Adaptive Biotechnologies by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after purchasing an additional 2,914 shares during the period. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.